期刊
ANNALS OF TRANSLATIONAL MEDICINE
卷 8, 期 8, 页码 -出版社
AME PUBL CO
DOI: 10.21037/atm.2020.02.119
关键词
Cirrhosis; clinical application; immunomodulatory effects; liver fibrosis; mesenchymal stem cells (MSCs)
资金
- National Natural Science Foundation of China [81971495, 81571564]
- CAMS Innovation Fund for Medical Sciences [2019-I2M-5-035]
- Natural Science Foundation of Jiangsu Province, China [BK20170152]
- Jiangsu Provincial Medical Youth Talent [BRA2017533, QNRC2016108]
- Six Talent Peaks Program of Jiangsu Province [YY-081]
- Nanjing Technological Development Program [201715054]
- Foundation of Jiangsu Collaborative Innovation Center of Biomedical Functional Materials
Liver fibrosis represents a common outcome of most chronic liver diseases. Advanced fibrosis leads to cirrhosis for which no effective treatment is available except liver transplantation. Because of the limitations of liver transplantation, alternative therapeutic strategies are an urgent need to find. Recently, mesenchymal stem cells (MSCs) based therapy has been suggested as an attractive therapeutic option for liver fibrosis and cirrhosis, based on the promising results from preclinical and clinical studies. Although the precise mechanisms of MSC transplantation are still not fully understood, accumulating evidence has indicated that MSCs eliminate the progression of fibrosis due to their immune-modulatory properties. In this review, we summarise the properties of MSCs and their clinical application in the treatment of liver fibrosis and cirrhosis. We also discuss the mechanisms involved in MSC-dependent regulation of immune microenvironment in the context of liver fibrosis and cirrhosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据